Drugs / Triticum Aestivum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06950138 | Jan 2023 → Jan 2025 | obesity disorder, vascular disorder | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06496100 Comparator | Jan → Nov 2024 | obesity due to congenital leptin deficiency | Coordinación de Investigación en Salud, Mexico | Unknown | No outcome recorded |
| Phase 3 | NCT06501248 Comparator | Jul 2022 → Aug 2024 | obesity disorder | Coordinación de Investigación en Salud, Mexico | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triticum Aestivum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496100 ↗ |
| Known as | wheat grass | “Triticum aestivum, or wheatgrass, is a known plant, used primary for its anti-inflammatory and antioxidant properties.” NCT06950138 ↗1“Triticum aestivum, better known as wheat grass, is a very common fiber in the diet of the world population” NCT06501248 ↗ |
| Route | Oral | “receive 500 mg capsules with lyophilized Triticum aestivum orally every 12 hours for 120 days” NCT06496100 ↗ |